Table 1.
Baseline Characteristics*
| Variable | Placebo n = 163 |
ISP n = 162 |
No CIMT Follow-up n = 25 |
|---|---|---|---|
| CIMT – mm | 0.811(0.098) | 0.810 (0.105) | 0.813 (0.082) |
| Age – yrs | 60.9 (6.9) | 60.8 (7.2) | 62.3 (7.8) |
| Ethnicity | |||
| White (non-Hispanic) | 110 (67%) | 97 (60%) | 16 (64%) |
| Black (non-Hispanic) | 10 (6%) | 12 (7%) | 3 (12%) |
| Hispanic | 21 (13%) | 31 (19%) | 4 (16%) |
| Asian | 22 (14%) | 21 (13%) | 2 (8%) |
| Unknown | - | 1 (<1%) | - |
| Education | |||
| ≤ High school | 5 (3%) | 13 (8%) | 1 (4%) |
| > High school | 158 (97%) | 149 (92%) | 24 (96%) |
| Smoking history | |||
| Current | 5 (3%) | 2 (1%) | 1 (4%) |
| Former | 59 (36%) | 68 (42%) | 8 (32%) |
| Never smoked | 99 (61%) | 92 (57%) | 16 (64%) |
| Body mass index – kg/m2 | 25.8 (23.2, 30.0) | 26.0 (22.8, 29.6) | 25.0 (23.0, 27.6) |
| Past use of hormone therapy | |||
| Yes | 111 (68%) | 118 (73%) | 16 (64%) |
| No | 52 (32%) | 44 (27%) | 9 (36%) |
| Age at menopause – yrs† | 50.0 (48.0, 52.0) | 50.0 (47.0, 52.0) | 48.5 (46.0, 50.0) |
| Time-since-menopause – yrs | |||
| <5 | 35 (22%) | 33 (20%) | 5 (20%) |
| 5–10 | 43 (26%) | 46 (28%) | 6 (24%) |
| >10 | 65 (40%) | 69 (43%) | 11 (44%) |
| Unknown | 20 (12%) | 14 (9%) | 3 (12%) |
| Type of menopause | |||
| Natural | 144 (88%) | 150 (93%) | 20 (80%) |
| Surgical | 18 (11%) | 12 (7%) | 5 (20%) |
| Unknown | 1 (<1%) | - | - |
*
Mean (SD) or median (25th, 75th percentile) for continuous variables and n (%).
†
Age at menopause could not be determined in 37 subjects.
ISP = isoflavone soy protein treatment group.
CIMT = carotid artery intima-media thickness.